Skip to Content
Merck
CN

C2174000

Cilazapril

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Cilazapril monohydrate

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C22H31N3O5 · H2O
CAS Number:
Molecular Weight:
435.51
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Cilazapril, European Pharmacopoeia (EP) Reference Standard

SMILES string

N21N(CCC[C@H]2C(=O)O)CCC[C@@H](C1=O)N[C@@H](CCc3ccccc3)C(=O)OCC.O

InChI

1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1

InChI key

JQRZBPFGBRIWSN-YOTVLOEGSA-N

grade

pharmaceutical primary standard

API family

cilazapril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Application

Cilazapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E Dervis et al.
Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 19(3), 31-34 (2010-10-27)
A 54-year-old woman presented with angiomatous lesions located on the upper extremities and right cruris. Histopathological findings were typical of Kaposi's sarcoma (KS). She had had mild to moderate psoriasis since she was 25 years old. She had been using
Fs Tian et al.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 118(4), 258-265 (2009-10-27)
This observational study aimed to investigate the effects of renin-angiotensin system (RAS) blockers on plasma adiponectin in subjects with metabolic syndrome (Mets) and differentiation, adiponectin expression of human omental (OM) and subcutaneous (SC) preadipocytes. Fifty-three patients with Mets were treated
Yan-Xing Zhang et al.
Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)
Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic
Eduardo Cantoni Rosa et al.
Arquivos brasileiros de endocrinologia e metabologia, 52(1), 65-75 (2008-03-18)
Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were
Jicheng Lv et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 53(1), 26-32 (2008-10-22)
Recent studies have shown that both steroids and angiotensin-converting enzyme (ACE) inhibitors improve kidney survival and decrease proteinuria in patients with immunoglobulin A nephropathy. In this study, we aim to investigate whether the addition of steroids to ACE-inhibitor therapy produces

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service